Farxiga Muscle Preservation Strategies: What the Evidence Says About Dapagliflozin and Skeletal Muscle

How dapagliflozin works

Dapagliflozin blocks sodium-glucose cotransporter 2 in the kidney, so more glucose is excreted in urine, with an osmotic diuresis [5]. Heart and kidney benefits appear with or without diabetes, while glucose lowering fades at low eGFR; the label does not recommend glycemic use below an eGFR of 45, while the 10 mg heart and kidney dose can be started down to 25 [5].

What the large dapagliflozin trials measured

DECLARE-TIMI 58 enrolled 17,160 adults with type 2 diabetes; major adverse cardiovascular events were 8.8% on dapagliflozin versus 9.4% on placebo (HR 0.93, not significant) [1]. DAPA-HF randomized 4,744 adults with heart failure and an ejection fraction of 40% or less; worsening heart failure or cardiovascular death was 16.3% versus 21.2% (HR 0.74) [2]. DELIVER randomized 6,263 adults with an ejection fraction above 40%; the primary outcome was 16.4% versus 19.5% (HR 0.82) [3]. DAPA-CKD randomized 4,304 adults with an eGFR of 25 to 75 and stopped early for efficacy; the primary composite was 9.2% versus 14.5% (HR 0.61) [4]. The results above are cardiovascular, heart failure and kidney outcomes; they do not address muscle mass, strength or physical performance.

What the label says about volume depletion

The label states that dapagliflozin causes an osmotic diuresis that may reduce intravascular volume, sometimes as symptomatic hypotension or transient creatinine changes [5]. It says to assess volume status and renal function before starting in older adults, people with renal impairment or low systolic blood pressure, and people taking diuretics, and to monitor after starting [5]. Volume-depletion events were 0.4% with placebo, 0.6% with 5 mg and 0.8% with 10 mg in the 12-trial glycemic pool, and 2.4% versus 2.5% in DECLARE [5]. The label also warns about ketoacidosis, which can present with blood glucose under 250 mg/dL, and says to withhold the drug, if possible, for at least 3 days before surgery or prolonged fasting [5].

Where sarcopenia guidance fits

EWGSOP2 defines sarcopenia as a muscle disease rooted in adverse muscle changes that accumulate across a lifetime [6]. Low muscle strength is its key characteristic, low muscle quantity or quality confirms the diagnosis, and poor physical performance indicates severe sarcopenia [6].

The Farxiga label's pre-treatment checks are renal function and volume status [5].

Is Farxiga approved for weight loss?

No. The label carries no weight-management indication; the approved uses are chronic kidney disease, heart failure and glycemic control in type 2 diabetes [5]. The four outcome trials discussed here do not establish whether any weight change on dapagliflozin reflects a change in muscle [1][2][3][4].